Peuler Jacob D, Warfield R K N, Phelps Laura E
Department of Pharmacology, Midwestern University, Downers Grove, IL, USA.
Metabolism. 2004 Feb;53(2):147-52. doi: 10.1016/j.metabol.2003.09.006.
Troglitazone and other thiazolidinediones (TZDs) are thought to relax arterial smooth muscle by directly inhibiting calcium channels in smooth muscle cell membranes. However, until recently such inhibition was only examined acutely, ie, within only seconds or minutes after administration of these agents to arterial smooth muscle preparations. Recently, a novel experiment was reported in which troglitazone caused a 2-phase relaxation of perfused resistance arteries, namely, an acute relaxation (within the first 20 minutes of treatment), which was blocked by a nonselective calcium channel blocker and a delayed relaxation (after 2 hours), which was not. We sought to determine if any of the 4 major potassium (K) channels in vascular smooth muscle play a role in the delayed relaxation. We incubated vascular contractile rings prepared from ventral tail arteries of rats with physiological buffer containing either 0 or 4 micromol/L troglitazone for 3 hours (4 micromol/L is typical of plasma levels from diabetic patients). Different K channel inhibitors (1 mmol/L 4-aminopyridine [4AP]; 1 mmol/L tetraethylammonium [TEA]; 5 micromol/L glyburide; 20 micromol/L barium) were coadministered with each level of troglitazone in additional preparations. Then these arterial rings were contracted with either norepinephrine (NE), arginine vasopressin (AVP), or high-K buffer. All contractions were significantly relaxed by troglitazone (P <.05). Only 4AP significantly attenuated troglitazone's relaxation of NE and AVP contractions (P <.05), though not high-K-induced contractions. TEA, glyburide, and barium had no such influence. Thus, for both adrenergic (NE) and nonadrenergic (AVP) contractions, the delayed arterial vasorelaxation by troglitazone may be mediated at least in part by activation of 4AP-sensitive K channels. Furthermore, the specific subtype of the channels involved is most likely those bound in the outer cell membrane where their effectiveness in terms of mediating relaxation would depend on an intact transmembrane K ion gradient.
曲格列酮和其他噻唑烷二酮类药物(TZDs)被认为可通过直接抑制平滑肌细胞膜上的钙通道来舒张动脉平滑肌。然而,直到最近,这种抑制作用仅在急性情况下进行了研究,即在将这些药物应用于动脉平滑肌制剂后仅数秒或数分钟内进行观察。最近,有一项新的实验报道称,曲格列酮可使灌注阻力动脉出现双相舒张,即急性舒张(治疗后的前20分钟内),这种急性舒张可被非选择性钙通道阻滞剂阻断;以及延迟舒张(2小时后),该延迟舒张则不受其影响。我们试图确定血管平滑肌中的4种主要钾(K)通道是否在这种延迟舒张中发挥作用。我们将从大鼠腹侧尾动脉制备的血管收缩环与含有0或4微摩尔/升曲格列酮的生理缓冲液一起孵育3小时(4微摩尔/升是糖尿病患者血浆水平的典型值)。在另外的制剂中,将不同的K通道抑制剂(1毫摩尔/升4-氨基吡啶[4AP];1毫摩尔/升四乙铵[TEA];5微摩尔/升格列本脲;20微摩尔/升钡)与每种浓度的曲格列酮共同给药。然后用去甲肾上腺素(NE)、精氨酸加压素(AVP)或高钾缓冲液使这些动脉环收缩。曲格列酮可使所有收缩均显著舒张(P<.05)。只有4AP能显著减弱曲格列酮对NE和AVP收缩的舒张作用(P<.05),但对高钾诱导的收缩则无此作用。TEA、格列本脲和钡没有这种影响。因此,对于肾上腺素能(NE)和非肾上腺素能(AVP)收缩,曲格列酮引起的延迟动脉血管舒张可能至少部分是由4AP敏感的K通道激活介导的。此外,所涉及通道的特定亚型很可能是那些位于细胞膜外侧的通道,其在介导舒张方面的有效性将取决于完整的跨膜K离子梯度。